BR112014012101A2 - métodos de tratamento de artrite psoriática (psa) usando os antagonistas de il- 17 e alelos de resposta ou não resposta à psa - Google Patents
métodos de tratamento de artrite psoriática (psa) usando os antagonistas de il- 17 e alelos de resposta ou não resposta à psaInfo
- Publication number
- BR112014012101A2 BR112014012101A2 BR112014012101A BR112014012101A BR112014012101A2 BR 112014012101 A2 BR112014012101 A2 BR 112014012101A2 BR 112014012101 A BR112014012101 A BR 112014012101A BR 112014012101 A BR112014012101 A BR 112014012101A BR 112014012101 A2 BR112014012101 A2 BR 112014012101A2
- Authority
- BR
- Brazil
- Prior art keywords
- psa
- response
- psoriatic arthritis
- antagonists
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
resumo patente de invenção: "métodos de tratamento de artrite psoriática (psa) usando os antagonistas de il- 17 e alelos de resposta ou não resposta à psa". a presente invenção refere-se aos novos métodos preditivos e terapias personalizadas para o tratamento da artrite psoriática (psa). especificamente, a presente invenção refere-se a métodos de tratamento de um paciente com psa por meio da administração seletiva um antagonista de il - 17, por exemplo, um anticorpo de il - 17, tal como secukinumab, para o paciente com psa com base de que o paciente é predisposto a ter uma resposta favorável ao tratamento com o antagonista de il - 17. também são descritos na presente invenção os métodos de diagnóstico úteis para prever a probabilidade de que um paciente com psa vai responder ao tratamento com um antagonista de il - 17, por exemplo, um anticorpo de il - 17, tal como secukinumab.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IQ3702011 | 2011-11-21 | ||
US201261624564P | 2012-04-16 | 2012-04-16 | |
PCT/US2012/041310 WO2013077907A1 (en) | 2011-11-21 | 2012-06-07 | Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014012101A2 true BR112014012101A2 (pt) | 2019-09-24 |
Family
ID=48470189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014012101A BR112014012101A2 (pt) | 2011-11-21 | 2012-06-07 | métodos de tratamento de artrite psoriática (psa) usando os antagonistas de il- 17 e alelos de resposta ou não resposta à psa |
Country Status (12)
Country | Link |
---|---|
US (1) | US20150064193A1 (pt) |
EP (1) | EP2783014A1 (pt) |
JP (1) | JP2015504430A (pt) |
KR (1) | KR20140097178A (pt) |
CN (1) | CN104011223A (pt) |
AR (1) | AR086907A1 (pt) |
AU (1) | AU2012341081B2 (pt) |
BR (1) | BR112014012101A2 (pt) |
CA (1) | CA2856252A1 (pt) |
MX (1) | MX2014006158A (pt) |
RU (1) | RU2014125071A (pt) |
WO (1) | WO2013077907A1 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
NZ608972A (en) | 2010-10-01 | 2015-09-25 | Moderna Therapeutics Inc | Engineered nucleic acids and methods of use thereof |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
CN110201187A (zh) | 2011-12-16 | 2019-09-06 | 现代泰克斯公司 | 经修饰的核苷、核苷酸和核酸组合物 |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
AU2013243952A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
CA2949236C (en) | 2014-05-15 | 2023-06-13 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
KR20170045240A (ko) * | 2014-09-10 | 2017-04-26 | 노파르티스 아게 | 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도 |
AR103172A1 (es) | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
US20160244520A1 (en) * | 2015-01-24 | 2016-08-25 | Abbvie Inc. | Compositions and methods for treating psoriatic arthritis |
AU2016347471B2 (en) | 2015-10-27 | 2023-08-03 | UCB Biopharma SRL | Methods of treatment using anti-IL-17A/F antibodies |
WO2020104943A2 (en) * | 2018-11-20 | 2020-05-28 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-il-23 specific antibody |
EP3980065A4 (en) * | 2019-06-04 | 2023-07-05 | Janssen Biotech, Inc. | SAFE AND EFFECTIVE METHOD OF TREATMENT OF PSORIAL ARTHRITIS WITH ANTI-IL23 SPECIFIC ANTIBODY |
EP4031570A1 (en) * | 2019-09-20 | 2022-07-27 | Novartis AG | Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists |
AU2022232007A1 (en) * | 2021-03-12 | 2023-10-26 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
CN114427001A (zh) * | 2022-01-29 | 2022-05-03 | 中日友好医院(中日友好临床医学研究所) | 基于78个snp位点评估阿达木单抗治疗银屑病有效性的试剂盒 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
EP3366702B1 (en) | 2005-12-13 | 2023-08-09 | Eli Lilly And Company | Anti-il-17 antibodies |
JP5068270B2 (ja) | 2006-01-31 | 2012-11-07 | ノバルティス アーゲー | 癌を処置するためのil−17アンタゴニスト抗体 |
GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
JP5237366B2 (ja) * | 2007-06-20 | 2013-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | 炎症性関節疾患に対する抗il−17a治療のための関節破壊のバイオマーカー |
CA2737636A1 (en) | 2008-09-29 | 2010-04-01 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
CA2769462A1 (en) * | 2009-07-28 | 2011-02-03 | Janssen Biotech, Inc. | Serum markers predicting clinical response to anti-tnf.alpha. antibodies in patients with psoriatic arthritis |
EP3299390A1 (en) * | 2010-10-08 | 2018-03-28 | Novartis AG | Methods of treating psoriasis using il-17 antagonists |
WO2012082573A1 (en) * | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
-
2012
- 2012-06-07 JP JP2014542299A patent/JP2015504430A/ja active Pending
- 2012-06-07 KR KR1020147013196A patent/KR20140097178A/ko not_active Application Discontinuation
- 2012-06-07 MX MX2014006158A patent/MX2014006158A/es unknown
- 2012-06-07 AU AU2012341081A patent/AU2012341081B2/en not_active Ceased
- 2012-06-07 BR BR112014012101A patent/BR112014012101A2/pt not_active IP Right Cessation
- 2012-06-07 CA CA2856252A patent/CA2856252A1/en not_active Abandoned
- 2012-06-07 US US14/358,504 patent/US20150064193A1/en not_active Abandoned
- 2012-06-07 CN CN201280057295.5A patent/CN104011223A/zh active Pending
- 2012-06-07 RU RU2014125071/10A patent/RU2014125071A/ru not_active Application Discontinuation
- 2012-06-07 WO PCT/US2012/041310 patent/WO2013077907A1/en active Application Filing
- 2012-06-07 EP EP12727081.7A patent/EP2783014A1/en not_active Withdrawn
- 2012-06-11 AR ARP120102076A patent/AR086907A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN104011223A (zh) | 2014-08-27 |
US20150064193A1 (en) | 2015-03-05 |
RU2014125071A (ru) | 2015-12-27 |
AR086907A1 (es) | 2014-01-29 |
KR20140097178A (ko) | 2014-08-06 |
MX2014006158A (es) | 2014-06-19 |
AU2012341081A1 (en) | 2014-05-29 |
EP2783014A1 (en) | 2014-10-01 |
JP2015504430A (ja) | 2015-02-12 |
AU2012341081B2 (en) | 2015-06-04 |
WO2013077907A1 (en) | 2013-05-30 |
CA2856252A1 (en) | 2013-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014012101A2 (pt) | métodos de tratamento de artrite psoriática (psa) usando os antagonistas de il- 17 e alelos de resposta ou não resposta à psa | |
BR112012008665A2 (pt) | tratamento de câncer | |
BR112014005410A2 (pt) | aproximação semântica | |
BR112015027830A2 (pt) | método e sistema de identificação de biomarcador | |
BR112013026828A2 (pt) | polipeptídeos de anticorpo que antagonizam cd40 | |
BR112014015152A2 (pt) | métodos e materiais para a avaliação da perda de heterozigosidade | |
BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
BR112015004229A2 (pt) | ensaios de diagnósticos e kits para a deteção de receptor 1 do folato | |
BR112013009376A2 (pt) | métodos para determinar isótipos de anticorpos antifármacos | |
BR112014011127A2 (pt) | métodos para tratar, diagnosticar e monitorar doença de alzheimer | |
BR112015027327A2 (pt) | composições e métodos para alterar a sinalização do mensageiro secundário | |
BR112015012482A2 (pt) | ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos | |
AR065910A1 (es) | Marcadores biologicos pronosticos de la respuesta de la artritis reumatoide a los antagonistas de los linfocitos b | |
AR088294A1 (es) | Determinacion de polimorfismos de un nucleotido simple utiles para predecir la respuesta clinica al acetato de glatiramero | |
BR112014021178A2 (pt) | determinação de orientações anatômicas | |
BR112015017403A2 (pt) | biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória | |
BR112015013771A2 (pt) | biomarcador preditivo de resposta ao tratamento de ativador do receptor alfa 7 nicotínico de acetilcolina | |
CL2012002415A1 (es) | Anticuerpo monoclonal aislado que se une al inhibidor de la via del factor tisular humano (tfpi); composicion farmacéutica que comprende dicho anticuerpo; procedimientos para tratar deficiencias o defectos genéticos o adquiridos en la coagulación; molecula de acido nucleico que codifica el anticuerpo; vector y célula huesped. | |
BR112015030003A2 (pt) | chapa de aço laminada a frio, chapa de aço laminada a frio galvanizada e método de produção da mesma | |
BR112012017483A2 (pt) | previsão e redução de aloimunogenicidade de terapêuticos de proteína | |
BR112014020213A2 (pt) | biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope | |
WO2014058976A3 (en) | Biomarkers predictive for clinical response for glatiramer acetate | |
BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
BR112014025768A2 (pt) | métodos de tratamento de espondilite anquilosante usando antagonistas de il-17 | |
BR112013030473A2 (pt) | meios e métodos para diagnóstico e tratamento de esclerose múltipla |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |